Protagonist Therapeutics Inc. logo

Protagonist Therapeutics Inc.

PTGX | NASDAQ
Chart Builder DCF Calculator
$144.98
+$1.98 (+1.38%)
At close: Sep 21, 2026, 4:00 PM ET
$144.61
-$0.37 (-0.26%)
Pre-market: Sep 22, 2026, 4:09 AM ET

Market Data

Market Cap
$9.2B
Enterprise Value
$8.55B
Beta
1.79
Average Volume
637.54K
Shares Outstanding (Diluted)
71.01M
Shares Change YoY
11.8%
Institutional Ownership
N/A
Exchange
NASDAQ
ISIN
US74366E1029

Price Performance

Price Change 1M
-5.5%
Price Change 3M
21.9%
Price Change 6M
39.0%
Price Change YTD
66.3%
Price Change 1Y
124.7%
Price Change 3Y
747.3%
Price Change 5Y
670.8%
1M CAGR (ann.)
-2.2%
1Y CAGR (ann.)
141.5%
5Y CAGR (ann.)
26.0%
All-Time CAGR
28.1%

Valuation

PE Ratio
140.76
Forward PE
102.66
PEG Ratio
-0.14
Forward PEG
-1.06
PS Ratio
33.06
Forward PS
48.40
PB Ratio
11.08
P/FCF Ratio
112.32
P/Adj. FCF Ratio
499.16
P/OCF Ratio
72.85
EV/Sales
30.32
EV/EBIT
101.38
EV/EBITDA
100.03
EV/FCF
103.00
Earnings Yield
0.7%
FCF Yield
0.9%
Adj. FCF Yield
0.2%

Financial Health

Net Cash
$782.58M
Total Debt
$9.22M
Cash & Short-Term Investments
$782.58M
Total Assets
$885.54M
Current Ratio
21.71
Quick Ratio
21.71
Debt / Equity Ratio
0.01
Debt / EBITDA
0.11
Debt / FCF
0.11
OCF / Debt
8.93
Interest Coverage
0.00
Altman Z-Score
126.60
Piotroski F-Score
6

Margins & Profitability

Gross Profit Margin
99.9%
Operating Profit Margin
20.7%
EBITDA Margin
30.3%
Net Profit Margin
29.4%
FCF Margin
29.4%
Adj. FCF Margin
6.6%
SBC / Revenue
17.7%
SBC Impact (per share)
-77.5%

Returns

Return on Assets
9.4%
Return on Equity
12.0%
Return on Invested Capital
6.7%
Return on Capital Employed
6.9%
Return on Tangible Assets
9.4%

Historical Growth (CAGR)

Revenue CAGR 3Y
-6.9%
Revenue CAGR 5Y
59.6%
Revenue CAGR 10Y
33.8%
EPS CAGR 3Y
-54.8%
EPS CAGR 5Y
579.0%
EPS CAGR 10Y
37.5%
FCF CAGR 3Y
-63.2%
FCF CAGR 5Y
213.9%
FCF CAGR 10Y
144.0%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
26
EPS Growth Next 3Y
52.1%
Revenue Growth Next 3Y
27.8%
Earnings Date
Nov 4, 2026
EPS Estimate (next Q)
$2.43
EPS Growth Est (next Q)
-491.9%
Revenue Est (next Q)
$240.13M
Revenue Growth Est (next Q)
4996.0%

Fair Value Estimates

Graham Number
$17.20
Graham Upside
-88.1%
Lynch Fair Value
$25.75
Lynch Upside
-82.2%
Price Target
$176.29
Price Target Upside
21.6%

Cash Flow

Operating Cash Flow
$82.25M
Free Cash Flow
$83.01M
Adj. Free Cash Flow
$18.68M
FCF Per Share
$2
OCF Per Share
$1.99
OCF/S Ratio
46.5%

Income Statement

Revenue
$281.99M
Gross Profit
$281.59M
Operating Income
$58.34M
EBITDA
$85.48M
Net Income
$82.91M
EPS (Diluted)
$1.03
Revenue / Employee
$2M
Profit / Employee
$588.01K
Employees
141

© 2026 bestshares.com. All rights reserved.